Digest Network Come funziona
Network
/
Società
Al
Non verificato

Alzheon, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteScienza

13 comunicati stampa

Guarda tutti i comunicati
02/12/2025
Scienza
Finanza
Medicina - Varie
Associazioni/Professionisti
Biotecnologia
Sanità
Farmaceutica
Salute
Industria
Alzheon Announces Peer-Reviewed Publication Providing Evidence for Hippocampal Volume as Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Alzheimer’s Disease
Fonte
Alzheon, Inc.
Emittente
Business Wire
1.00
0
19/11/2025
Eventi
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Alzheon to Present Multiple Clinical, Neuroimaging and Modeling Results for Oral Valiltramiprosate/ALZ-801 from Phase 2 and 3 Studies at CTAD Conference in San Diego, December 1–4, 2025
Fonte
Alzheon, Inc.
Emittente
Business Wire
1.00
0
14/10/2025
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
Alzheon Announces Peer-Reviewed Scientific Publication of Results from Pivotal APOLLOE4 Phase 3 Trial of Oral Valiltramiprosate/ALZ-801 in APOE4/4 Homozygous Individuals with Early Alzheimer’s Disease
Fonte
Alzheon, Inc.
Emittente
Business Wire
1.00
0
15/07/2025
Salute
Sanità
Farmaceutica
Biotecnologia
Web e Social Network
Eventi
Industria
Alzheon to Present Insights into Oral Valiltramiprosate/ALZ-801 Mode of Action and Clinical Efficacy at Dedicated Symposium at Alzheimer’s Association International Conference in Toronto on July 30th, 2025
Fonte
Alzheon, Inc.
Emittente
Business Wire
1.00
0
10/04/2025
Eventi
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Topline Results from Pivotal APOLLOE4 Phase 3 Trial of Oral Valiltramiprosate/ALZ-801 in Patients with Early Alzheimer’s Disease Carrying Two Copies of APOE4 Gene
Fonte
Alzheon, Inc.
Emittente
Business Wire
1.00
0
18/03/2025
Eventi
Industria
Scienza
Biotecnologia
Farmaceutica
Salute
Igiene alimentare
Medicina - Varie
Alzheon to Present Results from Pivotal APOLLOE4 Phase 3 Trial of Oral Valiltramiprosate/ALZ-801 at Dedicated Symposium at ADPD Conference in Vienna on April 1st, 2025
Fonte
Alzheon, Inc.
Emittente
Business Wire
1.00
0
25/02/2025
Scienza
Biotecnologia
Farmaceutica
Salute
Igiene alimentare
Medicina - Varie
Eventi
Industria
Alzheon Announces Two New Scientific Papers Ahead of APOLLOE4 Phase 3 Trial Topline Symposium at ADPD Conference in Vienna on April 1st, Marking 15 Pathbreaking Peer-Reviewed Publications from Alzheon
Fonte
Alzheon, Inc.
Emittente
Business Wire
1.00
0
07/01/2025
Mercato del lavoro
Eventi
Industria
Psichiatria
Scienza
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Alzheon Announces Appointment of Renowned Investor and Financial Executive Muneer A. Satter to Board of Directors
Fonte
Alzheon, Inc.
Emittente
Business Wire
1.00
0
18/09/2024
Industria
Scienza
Biotecnologia
Farmaceutica
Salute
Psichiatria
Medicina - Varie
New Alzheon Peer-Reviewed Scientific Publication Describes Study Design and Baseline Characteristics from APOLLOE4 Phase 3 Trial of Oral ALZ-801/Valiltramiprosate in APOE4/4 Homozygous Individuals with Early Alzheimer’s Disease
Fonte
Alzheon, Inc.
Emittente
Business Wire
1.00
0
23/07/2024
Psichiatria
Scienza
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
Eventi
Alzheon to Present Phase 2 Biomarker Trial Results and Baseline Characteristics from APOLLOE4 Phase 3 Trial of Oral ALZ-801/Valiltramiprosate in Patients with Early Alzheimer’s Disease at Alzheimer’s Association International Conference
Fonte
Alzheon, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0